Skip to content
OpenCapital
Get started

Nuvation Bio NUVB Contract Liabilities

Discontinued — last reported Q1 '25

Contract Liabilities at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$79M-72.9%
BillionToOne, Inc. logo
BillionToOne, Inc. BLLN
$0—
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$3.35M—

Segments

By product

See full
License$58.7M—
Research And Development Service Revenue$18.4M+9,100%
Royalty Revenue$300K—
Product Revenue$100K—

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Nuvation Bio’s 10-Q, filed May 7, 2025, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's contract liabilities?
Nuvation Bio (NUVB) reported contract liabilities of $13.61M in Q1 2025.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.